AN2 Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease

 

• Epetraborole Data from Recently Completed Phase 1 Study in Japanese Subjects Supports Use of Once Daily, 500 mg Dose in Japanese Patients
• Treatment-Refractory MAC Lung Disease Clinical Development Strategy to Focus Initially on Japan and U.S., Two Countries with Highest Prevalence of MAC Lung Disease
• Epetraborole Granted Orphan Medicinal Product Designation in NTM Lung Disease in European Union

https://www.biospace.com/article/releases/an2-therapeutics-provides-update-on-epetraborole-ex-u-s-development-plan-in-treatment-refractory-mac-lung-disease/